Investors and analysts can join the discussion by dialing (800) 836-8184 for domestic participants or (646) 357-8785 for international callers; the company recommends connecting ten minutes before the start time. A live audio webcast and supplementary slide deck will be accessible via the Events & Presentations portal on the Karyopharm investor website. An archived version of the briefing will be posted online approximately two hours following the conclusion of the event.

Karyopharm continues to focus on its core portfolio, led by the nuclear export inhibitor XPOVIO, which is currently marketed for relapsed or refractory multiple myeloma. Beyond its commercial operations, the company is actively investigating the efficacy of selinexor in treating myelofibrosis and exploring next-generation compounds like eltanexor for broader myeloproliferative neoplasms.